X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CAN-2409 is an investigational off-the-shelf replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene, in combination with valacyclovir is being investigated for the treatment pancreatic cancer.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
CAN-2409 (aglatimagene besadenovec) is an adenoviral replication-defective engineered gene construct encoding the thymidine kinase gene. It is being evaluated in combination with valacyclovir for the treatment of borderline resectable pancreatic ductal adenocarcinoma.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
The partnership aims to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).
Lead Product(s): CAN-3110,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CAN-3110
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Batavia Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 21, 2024
Details:
CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of patients with recurrent high-grade glioma (HGG) to improve overall survival.
Lead Product(s): CAN-3110,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CAN-3110
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. It has received fast track designation for NSCLC in combination with pembrolizumab.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
CAN-2409 (aglatimagene besadenovec) plus valacyclovir is a replication-defective adenovirus that is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. It has received fast track designation for NSCLC in combination with pembrolizumab.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
CAN-2409 (aglatimagene besadenovec) is an oncolytic viral immunotherapy that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. Data from the phase 2 trial of CAN-2409 in non-small cell lung cancer shows disease control rate of 77 percent in patients.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
rQNestin (CAN-3110) is a herpes simplex virus (HSV) replication-competent viral immunotherapy candidate engineered to enhance selective killing of malignant cells while sparing healthy normal neighboring cells.
Lead Product(s): CAN-3110,Cyclophosphamide
Therapeutic Area: Oncology Product Name: rQNestin
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
